Ayala Pharmaceuticals Net debt/EBITDA
Cos'è Net debt/EBITDA di Ayala Pharmaceuticals?
Net debt/EBITDA di Ayala Pharmaceuticals Inc. è 6.92
Qual è la definizione di Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA di aziende nel Health Care settore su NASDAQ rispetto a Ayala Pharmaceuticals
Cosa fa Ayala Pharmaceuticals?
advaxis (nasdaq: adxs) is a late -stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. the advaxis technology, using bioengineered live attenuated bacteria, listeria monocytogenes (lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.
Aziende con net debt/ebitda simili a Ayala Pharmaceuticals
- Admiral Plc ha Net debt/EBITDA di 6.91
- Dell Technologies Inc ha Net debt/EBITDA di 6.91
- RELX Plc ha Net debt/EBITDA di 6.91
- Smith & Nephew plc ha Net debt/EBITDA di 6.92
- Albireo Pharma Inc ha Net debt/EBITDA di 6.92
- BerGenBio ASA ha Net debt/EBITDA di 6.92
- Ayala Pharmaceuticals ha Net debt/EBITDA di 6.92
- Phillips 66 ha Net debt/EBITDA di 6.92
- Cardiff Oncology ha Net debt/EBITDA di 6.92
- CareTrust REIT Inc ha Net debt/EBITDA di 6.93
- Tomra Systems ASA ha Net debt/EBITDA di 6.93
- Jardine Matheson ha Net debt/EBITDA di 6.93
- Global Ship Lease Inc ha Net debt/EBITDA di 6.93